Cargando…
Impaired Neutralizing Antibody Response to COVID-19 mRNA Vaccines in Cancer Patients
There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for immunocompromised patients. In this study, we determined the neutralizing antibody response in 160 cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non...
Autores principales: | Zeng, Cong, Evans, John P., Reisinger, Sarah, Woyach, Jennifer, Liscynesky, Christina, Boghdadly, Zeinab El, Rubinstein, Mark P., Chakravarthy, Karthik, Saif, Linda, Oltz, Eugene M., Gumina, Richard J., Shields, Peter G., Li, Zihai, Liu, Shan-Lu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547525/ https://www.ncbi.nlm.nih.gov/pubmed/34704093 http://dx.doi.org/10.1101/2021.10.20.21265273 |
Ejemplares similares
-
Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
por: Zeng, Cong, et al.
Publicado: (2021) -
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
por: Evans, John P., et al.
Publicado: (2022) -
Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection
por: Evans, John P., et al.
Publicado: (2021) -
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer
por: Zeng, Cong, et al.
Publicado: (2022) -
Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H
por: Zeng, Cong, et al.
Publicado: (2021)